310 related articles for article (PubMed ID: 22991257)
1. Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C.
Arase Y; Kobayashi M; Suzuki F; Suzuki Y; Kawamura Y; Akuta N; Kobayashi M; Sezaki H; Saito S; Hosaka T; Ikeda K; Kumada H; Kobayashi T
Hepatology; 2013 Mar; 57(3):964-73. PubMed ID: 22991257
[TBL] [Abstract][Full Text] [Related]
2. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.
Arase Y; Suzuki F; Suzuki Y; Akuta N; Kobayashi M; Kawamura Y; Yatsuji H; Sezaki H; Hosaka T; Hirakawa M; Ikeda K; Kumada H
Hepatology; 2009 Mar; 49(3):739-44. PubMed ID: 19127513
[TBL] [Abstract][Full Text] [Related]
3. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy.
Hung CH; Lee CM; Wang JH; Hu TH; Chen CH; Lin CY; Lu SN
Int J Cancer; 2011 May; 128(10):2344-52. PubMed ID: 20669224
[TBL] [Abstract][Full Text] [Related]
4. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N
Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522
[TBL] [Abstract][Full Text] [Related]
5. A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan.
Yu ML; Lin SM; Chuang WL; Dai CY; Wang JH; Lu SN; Sheen IS; Chang WY; Lee CM; Liaw YF
Antivir Ther; 2006; 11(8):985-94. PubMed ID: 17302368
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon.
Ikeda M; Fujiyama S; Tanaka M; Sata M; Ide T; Yatsuhashi H; Watanabe H
J Gastroenterol; 2005 Feb; 40(2):148-56. PubMed ID: 15770398
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis.
N'Kontchou G; Paries J; Htar MT; Ganne-Carrie N; Costentin L; Grando-Lemaire V; Trinchet JC; Beaugrand M
Clin Gastroenterol Hepatol; 2006 Aug; 4(8):1062-8. PubMed ID: 16844421
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.
Arase Y; Ikeda K; Suzuki F; Suzuki Y; Saitoh S; Kobayashi M; Akuta N; Someya T; Koyama R; Hosaka T; Sezaki H; Kobayashi M; Kumada H
Intervirology; 2007; 50(1):16-23. PubMed ID: 17164553
[TBL] [Abstract][Full Text] [Related]
9. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
Imai Y; Tamura S; Tanaka H; Hiramatsu N; Kiso S; Doi Y; Inada M; Nagase T; Kitada T; Imanaka K; Fukuda K; Takehara T; Kasahara A; Hayashi N
J Viral Hepat; 2010 Mar; 17(3):185-91. PubMed ID: 19709362
[TBL] [Abstract][Full Text] [Related]
10. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
11. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
[TBL] [Abstract][Full Text] [Related]
12. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis.
Aizawa Y; Shibamoto Y; Takagi I; Zeniya M; Toda G
Cancer; 2000 Jul; 89(1):53-9. PubMed ID: 10897000
[TBL] [Abstract][Full Text] [Related]
13. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection.
Asahina Y; Tsuchiya K; Tamaki N; Hirayama I; Tanaka T; Sato M; Yasui Y; Hosokawa T; Ueda K; Kuzuya T; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Izumi N
Hepatology; 2010 Aug; 52(2):518-27. PubMed ID: 20683951
[TBL] [Abstract][Full Text] [Related]
14. Data mining model using simple and readily available factors could identify patients at high risk for hepatocellular carcinoma in chronic hepatitis C.
Kurosaki M; Hiramatsu N; Sakamoto M; Suzuki Y; Iwasaki M; Tamori A; Matsuura K; Kakinuma S; Sugauchi F; Sakamoto N; Nakagawa M; Izumi N
J Hepatol; 2012 Mar; 56(3):602-8. PubMed ID: 22027574
[TBL] [Abstract][Full Text] [Related]
15. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
Shindo M; Ken A; Okuno T
Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.
Tokita H; Fukui H; Tanaka A; Kamitsukasa H; Yagura M; Harada H; Okamoto H
J Gastroenterol Hepatol; 2005 May; 20(5):752-8. PubMed ID: 15853990
[TBL] [Abstract][Full Text] [Related]
17. Analysis of risk factors for hepatocellular carcinoma in patients with HBs antigen- and anti-HCV antibody-negative alcoholic cirrhosis: clinical significance of prior hepatitis B virus infection.
Uetake S; Yamauchi M; Itoh S; Kawashima O; Takeda K; Ohata M
Alcohol Clin Exp Res; 2003 Aug; 27(8 Suppl):47S-51S. PubMed ID: 12960507
[TBL] [Abstract][Full Text] [Related]
18. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
[TBL] [Abstract][Full Text] [Related]
19. Development of hepatocellular carcinoma after interferon therapy in chronic hepatitis C. Is it possible to reduce the incidence by ribanirin and IFN combination therapy?
Izumi N; Yasuhiro A; Kurosaki M; Onuki Y; Nishimura Y; Inoue K; Ueda K; Tsuchiya K; Nakanishi H; Uchihara M; Miyake S
Intervirology; 2005; 48(1):59-63. PubMed ID: 15785091
[TBL] [Abstract][Full Text] [Related]
20. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection.
Lai MS; Hsieh MS; Chiu YH; Chen TH
Hepatology; 2006 Jun; 43(6):1295-302. PubMed ID: 16729295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
